Ichnos: Ph1 Multi Open 2 part Dose Esc / Exp Single Agent ISB 1342 (Multiple Myeloma)

What is the Purpose of this Study?

If you choose to join this study, you will go through a screening period to find out if you are eligible. During this screening period, you will:
- Have a physical exam
- Have a heart scan (ECG)
- Have blood draws and give urine samples
- Have bone marrow samples taken
- Have whole-body X-rays and MRI or CT scans

If you are eligible to continue in the study after screening, you will get a dose of the study drug once a week for each drug cycle. Each drug cycle lasts 4 weeks. Your number of drug cycles will depend on your study doctor's assessment of how you are doing.

You will continue to visit our clinic for check-up visits to see how you are doing after you stop taking the study drug.

What is the Condition Being Studied?
Multiple Myeloma (MM)

Who Can Participate in this Study?

Adults diagnosed with MM who:

- Were previously treated with study therapy that might include proteasome inhibitors, immunomodulators, or anti-CD38 targeted therapies (e.g., daratumumab or isatuximab)

- Did not respond to the previous treatment or had their cancer come back

For more information about who can join this study, please contact the study team at 919-684-9220.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out if an experimental drug called ISB 1342 (study drug) is a safe and effective treatment for people with MM.

Study Details

Full Title
A Phase 1, First-in-Human, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects with Previously Treated Multiple Myeloma
Principal Investigator

Protocol Number
IRB:
PRO00103895

NCT:
NCT03309111
ClinicalTrials.gov
View on ClinicalTrials.gov